• Users Online: 140
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 18  |  Issue : 3  |  Page : 138-142

Combined sutureless gluefree conjunctival autograft with subconjunctival bevacizumab for treatment of primary pterygium


Department of Ophthalmology, Faculty of Medicine (For Girls), Al-Azhar University, Cairo, Egypt

Correspondence Address:
Mona M Aly
Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Nasr City 11754, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/DJO.DJO_29_17

Rights and Permissions

Purpose The aim of this study was to assess the efficacy of subconjunctival bevacizumab injection as adjuvant therapy in the prevention of recurrence following excision of pterygium and application of sutureless gluefree conjunctival autograft (SL/GF CAG). Patients and methods A prospective randomized comparative study was performed on 20 eyes of 20 patients with primary pterygium. They were divided into two groups: group A (10 eyes) had pterygium excision with SL/GF CAG and received subconjunctival 2.5 mg/0.1 ml of bevacizumab at the end of the surgery and group B (10 eyes) had pterygium excision with SL/GF CAG only followed by eye pressure patching for 24 h in both groups. Results SL/GF CAG was successful in all cases except in one (10%) eye in group B that developed conjunctival graft retraction on the first postoperative day necessitating resurgery. Adjuvant subconjunctival bevacizumab injection used in group A was well tolerated with no systemic or local side effects but in the term of recurrence, no statistically significant difference was reported between the two groups in the postoperative 6 months follow-up period. Conclusion SL/GF CAG is a novel technique for the treatment of primary pterygium. Augmentation of this technique with a single injection of bevacizumab by the end of surgery aiming at reducing the recurrence rate did not seem to provide any statistically significant difference than SL/GF CAG alone, although bevacizumab injection was well tolerated as an adjuvant therapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1474    
    Printed66    
    Emailed0    
    PDF Downloaded153    
    Comments [Add]    

Recommend this journal